Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
Type:
Grant
Filed:
May 16, 2006
Date of Patent:
June 7, 2011
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
Abstract: An immunogenic agent which comprises a killed strain of Burkholderia pseudomallei, or a combination of components thereof which combination produces a protective immune response in an animal to whom it is administered, and which comprises at least two members selected from the group consisting of (i) a lipopolysaccharide of Burkholderia pseudomallei, (ii) a capsular polysaccharide of Burkholderia pseudomallei and (iii) a protein of Burkholderia pseudomallei or an immunogenic variant thereof or an immunogenic fragment of either of these, or a nucleic acid which expresses said protein, immunogenic variant or immunogenic fragment thereof in a host animal; for use in the prevention or treatment of infection by Burkholderia pseudomallei and/or Burkholderia mallei.
Type:
Grant
Filed:
October 2, 2006
Date of Patent:
June 7, 2011
Assignee:
The Secretary of State for Defence
Inventors:
Stephen John Elvin, Gareth David Healey, Ethel Diane Williamson, James Edward Eyles, Sophie Jane Smither, Mitali Sarkar-Tyson, Timothy Philip Atkins, Michelle Nelson, Richard William Titball
Abstract: Methods, devices, kits and compositions for detecting the presence or absence of one or more helminthic coproantigens in a sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm, whipworm and/or hookworm in a fecal sample from a mammal and may also be able to distinguish between one or more helminth infections. Confirmation of the presence or absence of roundworm, whipworm and/or hookworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.
Type:
Grant
Filed:
May 18, 2009
Date of Patent:
May 31, 2011
Assignees:
Idexx Laboratories, Inc., Divergence, Inc.
Inventors:
David Allen Elsemore, Jinming Geng, Laurie A. Flynn, Michael Crawford
Abstract: The invention concerns the use of a fiber modified with functions capable of interacting with microbial cell wall proteins for immobilizing micro-organisms in hygiene products. Those functions are particularly capable of interacting with anionic groups and amine groups, and are especially cationic groups and aldehydes, respectively. The fibers may be synthetic or cellulosic. Also hygiene products containing these fibers are described.
Type:
Grant
Filed:
December 6, 2007
Date of Patent:
May 24, 2011
Assignee:
SCA Hygiene Products AB
Inventors:
Arie Besemer, Dorine Lisa Van Brussel-Verraest, Anne-Mieke Verwilligen, Gunilla Himmelmann, Kent Malmgren, Bo Andreasson, Carolyn Berland
Abstract: The present disclosure provides systems for the rapid and sensitive detection of organisms and molecules in samples. Reactants that produce Raman-active products are used in combination with Raman light scattering. The present disclosure can also be used to measure enzyme-kinetics.
Type:
Grant
Filed:
April 16, 2008
Date of Patent:
May 24, 2011
Assignee:
Sword Diagnostics, Inc.
Inventors:
Neal Arthur Siegel, Samar Kumar Kundu, Charles Lester Ginsburgh
Abstract: According to the present invention, an antibody against a Panton-Valentine leukocidin toxin contained in Staphylococcus aureus, a method and a kit for detecting the toxin with the use of the antibody, and a pharmaceutical composition containing an antibody against a Panton-Valentine leukocidin toxin for treating PVL infection caused by Staphylococcus aureus containing PVL are provided. Also, an antibody which is capable of binding to Panton-Valentine leukocidin F and has no cross-reactivity to LukD and/or HlgB and an antibody which is capable of binding to Panton-Valentine leukocidin S and has no cross-reactivity to at least one of LukE, HlgC, and HlgA are provided.
Abstract: Chalazia and hordeola are the most common lesions occurring in the human eyelid, and often recurrences are managed by surgical intervention to remove fatty inclusions within the lid with associated inflammatory reaction. The present invention provides non-surgical methods of treating chalazia, hordeola and cutaneous infections comprising the administration of compositions comprising botulinum toxin. The present invention provides methods that effectively block meibum secretion from the meibomian glands, reduce sebaceous bacterial culture media on skin, and sebaceous secretion from the glands of Zeis. Decreased production of meibum and associated fatty substances resulting from the methods of the present invention, decrease gland blockage and tissue inspissations, resulting in reduced recurrence of chalazia, hordeola and related inflammatory reactions and lesions.
Type:
Grant
Filed:
January 22, 2008
Date of Patent:
May 17, 2011
Assignee:
Botulinum Toxin Research Associates, Inc.
Abstract: Recombinant fragments of Factor C are disclosed. These proteins and peptides show great potency in recognizing, binding to, neutralizing and removing endotoxin. These molecules can thus be used for anti-microbial, anti-endotoxin, and anti-sepsis therapy. SSCrFCES is a 38 kDa protein representing the LPS-binding domain of Factor C. The ability of SSCrFCES to bind lipid A was analyzed using an ELISA-based assay as well as surface plasmon resonance. Surface plasmon resonance similarly carried out for SSCrFC-sushi-1,2,3-GFP, SSCrFC-sushi-1GFP, and SSCrFC-sushi-3GFP confirmed their superior affinity for endotoxin. The 50% endotoxin-neutralizing concentration of SSCrFCES against 200 EU of endotoxin is 0.069 ?M, suggesting that SSCrFCES is an effective inhibitor of LAL coagulation cascade. Although partially attenuated by human serum, as low as 1 ?M of SSCrFCES inhibits the LPS-induced secretion of hTNF-? and hIL-8 by THP-1 and human pheripheral blood mononuclear cells with a potency more superior than polymyxin B.
Abstract: The present invention addresses an ongoing need in the art to improve the stability of immunogenic compositions such as polysaccharide-protein conjugates and protein immunogens. The invention broadly relates to novel formulations which stabilize and inhibit precipitation of immunogenic compositions. More particularly, the invention described hereinafter, addresses a need in the art for formulations which stabilize and inhibit particulate formation (e.g., aggregation, precipitation) of immunogenic compositions which are processed, developed, formulated, manufactured and/or stored in container means such as fermentors, bioreactors, vials, flasks, bags, syringes, rubber stoppers, tubing and the like.
Type:
Grant
Filed:
April 19, 2007
Date of Patent:
May 3, 2011
Assignee:
Wyeth LLC
Inventors:
Lakshmi Khandke, Ronald Malone, Xudong Yang, Hanyoung Han, Jee Loon Look, Zhaowei Jin, Robert C. Seid, Jr., Ying Chen
Abstract: Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO.
Abstract: Provided are a method for detecting biomaterials, a method for fabricating a chip for biomaterial detection and a chip for biomaterial detection. The method for detecting biomaterials is characterized by comprising the steps of: (S1) immobilizing polydiacetylene liposomes onto a substrate; (S2) linking the polydiacetylene liposomes together and layering them on the substrate; (S3) immobilizing a material which forms a complementary binding with a subject biomaterial to be detected onto the polydiacetylene liposomes; (S4) exposing the resulted polydiacetylene liposome to UV light so as to form a chip for biomaterial detection; (S5) applying the subject biomaterial to be detected to the chip for biomaterial detection for reaction; and (S6) measuring a fluorescent signal from the chip for biomaterial detection.
Type:
Grant
Filed:
December 31, 2008
Date of Patent:
April 26, 2011
Assignee:
Sungkyunkwan University Foundation for Corporate Collaboration
Inventors:
Sang Jun Sim, Jun Pyo Kim, Cheol Hee Park
Abstract: The invention relates to a recombinant immunogenic composition from Rickettsia typhi. The invention also relates to a method for the use of the recombinant proteins in detection and diagnostic assays and as a component in formulations for the induction of an anti-R. typhi immune response.
Type:
Grant
Filed:
July 27, 2007
Date of Patent:
April 19, 2011
Assignee:
The United States of America as represented by the Secretary of the Navy
Abstract: The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of the Streptococcus, wherein the genomic fragment comprises at least a functional part of a fragment identifiable by hybridization in Streptococcus suis to a nucleic acid or fragment thereof.
Abstract: Disclosed are novel synthetically-modified B. thuringiensis chimeric crystal proteins having improved insecticidal activity against coleopteran, dipteran and lepidopteran insects. Also disclosed are the nucleic acid segments encoding these novel peptides. Methods of making and using these genes and proteins are disclosed as well as methods for the recombinant expression, and transformation of suitable host cells. Transformed host cells and transgenic plants expressing the modified endotoxin are also aspects of the invention.
Abstract: A method is disclosed for producing a polypeptide with a modified activity or stability, by replacing an arginine residue capable of being ADP-ribosylated with a tryptophan or a phenylalanine. In one embodiment, compositions are provided that include polypeptides, such as alpha defensin, with arginine-to-tryptophan or arginine-to-phenylalanine substitutions, where the arginine residue is capable of being ADP-ribosylated. In another embodiment, methods are disclosed for modifying an immune response in a subject.
Type:
Grant
Filed:
April 24, 2009
Date of Patent:
April 12, 2011
Assignees:
The United States of America as represented by the Secretary of the Department of Health and Human Services, University of Massachusetts
Inventors:
Joel Moss, Linda Stevens, Christelle Bourgeois, Rita Bortell
Abstract: The present invention relates to methods of compositions comprising RegIII and HIP/PAP proteins, including the use of such proteins as diagnostic and therapeutic targets.
Type:
Grant
Filed:
February 5, 2008
Date of Patent:
April 12, 2011
Assignee:
The Board of Regents of the University of Texas System
Inventors:
Lora V. Hooper, Heather L. Cash, Cecilia V. Whitham
Abstract: The present disclosure identifies methods and compositions for modifying photoautotrophic organisms as hosts, such that the organisms efficiently convert carbon dioxide and light into n-alkanes, and in particular the use of such organisms for the commercial production of n-alkanes and related molecules.
Type:
Grant
Filed:
September 10, 2010
Date of Patent:
April 5, 2011
Assignee:
Joule Unlimited, Inc.
Inventors:
Nikos Basil Reppas, Christian Perry Ridley
Abstract: Methods and compositions for the detection of disease caused by infectious agents and microbes are provided. In particular, methods and compositions comprising novel combinations of nucleic acid amplification and drug susceptibility technologies are provided. In certain embodiments, the present invention enables the detection of infectious agents and microbes as well as providing information concerning the viability status of the agent or microbe. In one embodiment, the present invention is used for the detection of mycobacterial infections, including, but not limited to, tuberculosis.
Type:
Grant
Filed:
April 7, 2008
Date of Patent:
April 5, 2011
Assignee:
Sequella, Inc.
Inventors:
Matthew C. Mulvey, Leo Einck, Katherine Sacksteder
Abstract: The invention discloses the Moraxella catarrhalis outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding OMP106 polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses to M. catarrhalis and M. catarrhalis OMP106 polypeptides and OMP106-derived polypeptides in animals.
Type:
Grant
Filed:
August 14, 2009
Date of Patent:
March 29, 2011
Assignee:
Emergent Product Development Gaithersburg, Inc.
Inventors:
Kenneth Tucker, Laura Plosila, Ulrich F. Tillman
Abstract: A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen.
Type:
Grant
Filed:
May 10, 1999
Date of Patent:
March 29, 2011
Assignee:
Trident Pharmaceuticals, Inc.
Inventors:
Timothy Raymond Hirst, Neil Andrew Williams, Andrew Morgan, Andrew Douglas Wilson, Lucy Amber Bird